Research programme: liposomal angiogenesis stimulants - EndovascAlternative Names: Liposomal angiogenesis stimulants research programme - Endovasc
Latest Information Update: 24 Apr 2007
At a glance
- Originator Endovasc
- Mechanism of Action Angiogenesis inducing agents; Intercellular signalling peptide and protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 01 Jun 1999 Preclinical development for Cardiovascular disorders in USA (Unknown route)